Tech Company Inital Public Offerings
Sana Biotechnology IPO
Headquartered in Seattle, Sana Biotechnology is now a public company.
Transaction Overview
Company Name
Announced On
2/4/2021
Transaction Type
IPO
Amount
$322,500,000
Proceeds Purpose
Use of proceeds for the Sana Biotechnology IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
188 East Blaine St. 400
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Undisclosed
Website
Email Address
Overview
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Harr
Chief Financial Officer
Nate Hardy
Chief Technical Officer
Ed Rebar
VP - Bus. Development
Christian Hordo
VP - General Counsel
James MacDonald
VP - Operations
Shanna Peek
VP - Product Management
Robin Andrulevich
VP - R & D
Sunil Agarwal
Browse more venture capital transactions:
Prev: 2/4/2021: TouchCast venture capital transaction
Next: 2/5/2021: Slync venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs